Obstet Gynecol by Sinno, Abdulrahman K. et al.
Human Papillomavirus Genotype Prevalence in Invasive Vaginal 
Cancer from a Registry-Based Population
Abdulrahman K. Sinno, MD1, Mona Saraiya, MD, MPH2, Trevor D Thompson, BS2, Brenda 
Y. Hernandez, PhD, MPH3, Marc T. Goodman, PhD, MPH3, Martin Steinau, PhD4, Charles F. 
Lynch, PhD, MD5, Wendy Cozen, DO, MPH6, Maria Sibug Saber, MD6, Edward S. Peters, 
ScD, DMD7, Edward J. Wilkinson, MD8, Glenn Copeland, MBA9, Claudia Hopenhayn, PhD, 
MPH10, Meg Watson, MPH2, Christopher Lyu, MPA12, and Elizabeth R. Unger, PhD, MD4
1The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns 
Hopkins University and Division of Gynecologic Oncology Emory University Department of 
Gynecology and Obstetrics, Atlanta, GA
2Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and 
Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
3University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI
4Division of High-Consequence Pathogens and Pathology, National Center for Emerging and 
Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA
5Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA
6Norris Comprehensive Cancer Center and Department of Pathology, Keck School of Medicine, 
University of Southern California, Los Angeles, CA
7Department of Epidemiology, School of Public Health, Louisiana State University Health 
Sciences Center, New Orleans, LA
8Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, 
University of Florida, Gainesville, FL
9Michigan Department of Community Health, Lansing, MI
10Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY
11Florida Department of Health, Tallahassee, FL
12Battelle Memorial Institute, Durham, NC
Abstract
Objective—To describe the human papillomavirus (HPV) genotype distribution in invasive 
vaginal cancers diagnosed prior to the introduction of the HPV vaccine, and evaluate if survival 
differed by HPV status.
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Methods—Four population-based registries and three residual tissue repositories provided 
formalin-fixed, paraffin-embedded tissue from microscopically confirmed primary vaginal cancer 
cases diagnosed between 1994 and 2005 that were tested by L1 consensus polymerase chain 
reaction with type-specific hybridization in a central laboratory. Clinical, demographic, and all-
cause survival data were assessed by HPV status.
Results—Sixty cases of invasive vaginal cancer were included. HPV was detected in 75% (45) 
and 25% (15) were HPV negative. HPV 16 was most frequently detected (55%, 33/60) followed 
by HPV 33 (18.3%, 11/60). Only one case was positive for HPV 18 (1.7%) Multiple types were 
detected in 15% of the cases. Vaginal cancers in women < 60 were more likely to be HPV 16 or 
HPV 18 positive (HPV 16/18) than older women; 77.3% vs. 44.7% (P = .038). The median age at 
diagnosis was younger in the HPV16/18 (59 years) group vs. other HPV positive (68 years) and no 
HPV (77 years) (P =.003). The HPV distribution did not significantly vary by race or ethnicity or 
place of residence. The 5-year unadjusted all-cause survival was 57.4% for women with HPV-
positive vaginal cancers vs. 35.7% among those with HPV-negative tumors (p=0.243).
Conclusion—Three quarters of all vaginal cancers in the United States had HPV detected, much 
higher than previously found , and 57% could be prevented by current HPV vaccines, .
Introduction
Vaginal cancer accounts for less than two percent of all gynecologic malignancies, with an 
annual incidence rate of 0.7 per 100,000 and 1,178 new cases per year for 2005–2009.1,2 
The 5-year relative survival rate for squamous cell carcinoma of the vagina is 54%3,4.The 
etiology of vaginal cancer varies by histology. Squamous cell carcinoma accounts for 
80-90% of all cases and is associated with a prior history of cervical carcinoma, prior 
irradiation for anogenital cancer, and human papillomavirus 16 (HPV 16).5 Some of the risk 
factors for vaginal carcinoma are also indicators of either increasing acquisition or 
decreasing clearance of HPV (multiple lifetime sexual partners, age at first intercourse, 
immunosuppression, cigarette smoking). Others are non-HPV-related risk factors such as 
chronic pessary use, surgical menopause, or prior hysterectomy. 67
HPV DNA has been detected in 55-64% of invasive vaginal cancers; 8-10 however, these 
studies have been limited by small sample sizes, due to low numbers of vaginal cancers or 
HPV testing that is limited to HPV 16 or HPV 18 detection. Furthermore, these samples 
were convenience samples from single institutions and not population-based studies. HPV 
vaccines provide immunity to HPV 16 and HPV 18 and cross-immunity to other HPV 
types, 11 and are expected to reduce the incidence of HPV-associated cancers, such as 
vaginal cancer. The HPV type distribution in these cancers should also shift following 
vaccine introduction. The aims of our study were to describe the HPV genotype distribution 
in invasive vaginal cancers diagnosed prior to the introduction of the vaccine and evaluate if 
survival differed by HPV status.
Materials and Methods
The Centers for Disease Control and Prevention Central Cancer Registries study was 
designed to provide a baseline prevalence of HPV types in HPV-associated cancer cases 
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from participating population-based cancer registries. Four population-based registries and 
three residual tissue repositories provided formalin-fixed paraffin-embedded tissue from 
microscopically confirmed primary vaginal cancer cases diagnosed between 1994 and 2005. 
One formalin fixed, paraffin embedded tissue block from each case was provided.
Sample processing, extraction, and HPV testing have been previously described12,13. 
Briefly, serial sections were cut using precautions to prevent contamination between cases. 
Hematoxylin and Eosin staining of first and last section was used to confirm presence of 
representative material. DNA extracts were tested with the Linear Array HPV Genotyping 
Test (Roche Diagnostics, Indianapolis, IN). Samples with negative or inadequate linear 
array results were re-tested with the INNO-LiPA HPV Genotyping Assay (LiPA, 
Innogenetics, Gent, Belgium). Samples failing both assays were considered inadequate and 
were not, therefore, included in the final analysis.
De-identified demographic (age, sex, population size), clinical (year of diagnosis, history of 
other cancers), pathologic (sub site, stage, grade), and survival data for cancer cases were 
available from each registry and tabulated. The Pearson chi-square test or Fisher's exact test 
was used for discrete variables and the Kruskal-Wallis rank sum test for continuous 
variables. De-identified demographic (age, sex, population size), clinical (year of diagnosis, 
history of other cancers), pathologic (sub site, stage, grade), and survival data for cancer 
cases were available from each registry. Five-year all-cause survival estimates are presented 
as Kaplan-Meier estimates with statistical testing performed using the log-rank test. A Cox 
proportional hazards model was used to determine the effect of HPV positivity on five-year 
all-cause survival after adjusting for age. Due to the small number of events (26 deaths), 
additional covariates such as stage and treatment were not included to avoid over fitting the 
model. The statistical analyses were performed using SAS 9.2 (Statistical Analysis 
Software, Cary, NC) and R version 2.15.2. The Centers for Disease Control and Prevention 
and each participating state received approval for the institutional review board for the 
study.
Results
One block from each of the 71 cases was cut and submitted. Of these, 60 cases had 
representative tissue and were successfully tested and 11 blocks did not contain 
representative tissue. The median age at diagnosis was 65, with 63% being 60 years of age 
or older (Table 1). At 76%, whites were the largest group in the sample. HPV DNA was 
found in 75% (45/60) of cases. HPV 16 was the most common type detected (55%, 33/60). 
The second most common was HPV 33, with 18% (11/60) of cases positive. Only one case 
was positive for HPV 18 (1.7%). In 15% of cases (9/60) multiple types were detected (Fig 1) 
but for 8 of 9 of those cases, HPV 16 was also detected and among 5/9 of those cases both 
HPV 16 and 33 were found .
Ninety one percent of women under the age of 60 were HPV positive, with most HPV types 
being HPV 16/18 (77.3%). Among the vaginal cancer cases in women 60 years of age and 
older, approximately two thirds were positive for HPV, and the proportion of HPV 16/18 
was lower (44.7%); p=0.038 . The median age at diagnosis was younger in the HPV 16/18 
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group (59 years of age) vs other HPV positive (68 years) and no HPV (77 years) (P = .003). 
The HPV distribution did not significantly vary by race or ethnicity, or rural or urban 
residence (Table 1).
Among all cases, 86% (49/57) were found to be squamous cell carcinomas, whereas 14% 
(8/57) were adenocarcinomas. Of the squamous cell carcinomas, 31 cases (63.3%) were 
positive for HPV 16/18, as opposed to only 25% of adenocarcinomas (P = 0.08). Stage at 
diagnosis was not statistically different among the HPV subtypes.
The unadjusted all-cause survival for all patients with vaginal cancer who were positive for 
any HPV was 57.4% vs 35.7% for patients who were HPV negative (P = 0.243). The 
unadjusted hazard ratio comparing HPV positive to HPV negative was 0.62 (95% CI 0.28–
1.39). However after adjusting for age, the hazard ratio was 1.57 (95% CI 0.63- 3.91) (Fig 2)
Discussion
In this multicenter study which spanned 11 years , of the 60 samples examined, 75% were 
HPV positive, much higher than most previously published results 8,10,14-16. Ostrow et al 8 
found HPV in 21% of 14 patients by using in situ hybridization. Using southern blot 
hybridization, Ikenberg et al , found 55% of 18 patients positive for HPV10. Koyamatsu and 
colleagues15 and Ferreira et al 16both used polymerase chain reaction for detection and 
found HPV in 53% and 81% of 40 and 21 patients, respectively.
It is possible that our HPV detection rate, which is on the higher end of the reported 
spectrum, is secondary to careful tissue selection, optimized extraction and the inclusion of a 
second PCR assay if the first assay was unsatisfactory. 13,17
HPV 16 was the most commonly detected type with 33/60 of the samples positive. HPV 33 
was detected in 11/60 cases and HPV 18 was only detected in 1/60 cases. Of note, 45% of 
cases positive for HPV 33 were also co-infected with HPV 16. HPV 33 has not been 
previously reported to have such a high prevalence in vaginal cancer. The currently licensed 
HPV vaccines protect against HPV 16 and 18 and our study found that 57% of vaginal 
cancers could theoretically be prevented. These vaccines do not provide primary coverage 
for HPV 33, the second most common HPV genotype found in our study. However, Wheeler 
and co-workers showed vaccination with the quadrivalent vaccine, despite only including 4 
HPV types, reduced the infection rate of related HPV types 31, 33, 45, 52, and 58 by 17.7% 
(95% confidence interval [CI], 5.1% to 28.7%) in pre-invasive cervical lesions.18 Cross-
immunity secondary shared characteristics between the HPV subtypes have been proposed 
as the mechanism behind this reduction. These results could theoretically be extrapolated to 
vaginal cancer but further studies are needed.
Previous studies have attributed a longer overall survival for vaginal cancer cases that were 
HPV positive.9,19 Our study did not show a statistically significant longer unadjusted 
survival). The median age in our population for HPV 16 or 18 positive cancers was 18 years 
younger than those who were HPV-negative. After adjusting for age, the survival hazard 
ratio for HPV positivity changed from 0.62 to 1.57 but this remained statistically 
insignificant. This could be partially explained by the younger age at diagnosis of women 
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with HPV- positive tumors. Younger patients are likely to tolerate more aggressive 
treatment and have better functional status and less co-morbidity. These results, if validated 
by larger sample sizes, could show that age-adjusted HPV positivity in vaginal cancer is a 
poorer prognostic marker and a marker of more aggressive cancers. However, ideally, we 
would have a larger sample size to control for additional variables such as stage and 
treatment.
We acknowledge several limitations to our study, one of which is the small sample size, 
which is attributable to the rarity of the disease. This small sample size yields low statistical 
power and limits the ability to interpret the data. Vaginal cancer is, however, an extremely 
rare disease and this is the cumulative data of 7 centers over 10 years. Another limitation in 
this data is that variables were missing from some cases such as stage and residence (12 and 
6 samples respectively). This is an unfortunate problem with retrospectively collected data.
Similar to other reports20,21, 76% of the samples were obtained from Caucasian patients 
76% of the samples were obtained from Caucasian patients, which potentially limits the 
generalizability of this data to other races. As with all studies based on extracted DNA, the 
detection of HPV DNA does not necessarily prove its involvement in malignant 
transformation versus its incidental presence. Another limitation is the use of formalin-fixed 
tissue blocks, which could potentially underestimate the HPV prevalence rate.
This study describes the prevalence of HPV in vaginal cancer. Given that the majority of 
vaginal cancers are positive for HPV 16, it is expected that if girls are vaccinated as 
recommended and coverage is high, we may anticipate a decrease in vaginal cancers by up 
to 57%, . 21,22
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Figure 1. HPV Genotype Distribution in Vaginal Cancer Cases (n = 60) HPV Typing of Cancers 
Study
Fig 1*Multiple types includes human papillomavirus (HPV) 16/33 (n = 5 56%) HPV 16 / 35 
(n = 1, 11%) HPV 16/66 (n = 1, 11%) HPV 16/81 (n = 1, 11%), HPV 51 / 82 (n = 1, 11%).
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5-year all-cause survival by HPV status among vaginal cancer patients. Note: Five-year 
unadjusted survival estimates are presented as Kaplan-Meier estimates with statistical 
testing performed using the log-rank test.
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